SAN CARLOS, USA – IncellDx today announces that Bruce Patterson MD, CEO of IncellDx, will present on the diagnosis, treatment and immunopathogenesis of chronic COVID-19 (PASC), also known as long COVID or long haul COVID, at the International TLC (How to Treat Long Covid) Conference. The International TLC Conference is one of the first in the world to bring together global specialist experts who are currently researching or developing treatments for long COVID.
Who: Bruce Patterson MD, CEO of IncellDx and the www.covidlonghaulers.com resource for those suffering from chronic COVID-19 (PASC)
What: International TLC (How to Treat Long Covid) Conference
When: Saturday, June 19th from 9:10 to 9:35 am Eastern Time
Where: Virtual event – to register click here
According to the National Institutes of Health (NIH), it is estimated that about 30 percent of people who have been infected with SARS-CoV-2 continue to experience symptoms long past the time that they have “recovered” from the initial stages of COVID-19 illness. These patients experience long COVID as fatigue, shortness of breath, “brain fog,” sleep disorders, fevers, gastrointestinal symptoms, anxiety and depression, among other symptoms. These symptoms persist for months and can range from mild to incapacitating. In some cases, new symptoms arise well after the time of infection, or evolve over time.
For more information about the TLC Conference, click here.
Bruce K. Patterson, M.D.
CEO & Founder of IncellDx and www.covidlonghaulers.com
Bruce K. Patterson, MD is a leading researcher on the effects of viral pathogens on the human immune system. His pioneering technologies and findings have contributed to advances in detection, prognosis and treatment of patients infected with HIV, HPV and cervical cancer, COVID-19 and other diseases.
Using PCR-driven in situ hybridization and flow cytometry to detect viral DNA and RNA within infected cells, Dr. Patterson and colleagues demonstrated that HIV entered and multiplied in the host cells in a stealthy fashion that eluded discovery. This groundbreaking work was published in the peer reviewed journal Science. He also developed a new method to investigate the effect of antiretroviral therapy within the infected host cell and published this discovery in the peer reviewed journal Lancet. Dr. Patterson continues his work on HIV-1 pathogenesis and reservoirs at Stanford University School of Medicine, where he previously served as Medical Director of Diagnostic Virology at Stanford University Hospitals and Clinics, director of clinical virology, and co-director of the AIDS Research Center.
Dr. Patterson received his undergraduate degree in microbiology from the University of Michigan and his MD from Northwestern, where he later served as Chief Resident of Pathology at Northwestern Memorial Hospital. He has authored more than 150 manuscripts and book chapters.
Dr. Patterson serves as CEO of IncellDx, where he is developing a new paradigm for predicting, identifying and treating long COVID-19 and other viral pathogens that impair the immune system’s ability to function effectively.
IncellDx, Inc., located in San Carlos, California, is a single-cell, molecular diagnostics company dedicated to revolutionizing healthcare, one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company’s focus is on critical life threatening diseases in the areas of COVID-19, infectious disease and oncology/immuno-oncology, including cervical, head and neck, lung, bladder and prostate cancers.
For more information: